The interferon-free regimen of ABT-@ ( a protease inhibitor ) , ritonavir , ombitasvir ( an NS@A inhibitor ) , dasabuvir ( a non-nucleoside polymerase inhibitor ) , and ribavirin has shown efficacy in patients with hepatitis C virus ( HCV ) genotype @b infection-the most prevalent subgenotype worldwide .